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ABSTRACT
Background: Cancer patients often do not make informed decisions about clinical trial
participation. This study evaluated whether a web-based decision aid (DA) could support trial
decisions compared to our cancer center’s website.
Methods: Adults diagnosed with cancer in the past six months who had not previously
participated in a cancer clinical trial were eligible. Participants were randomized to view the DA
or our cancer center’s website (enhanced usual care; UC). Controlling for whether participants
had heard of cancer clinical trials and educational attainment, multivariable linear regression
examined group on knowledge, self-efficacy for finding trial information, decisional conflict
(values clarity and uncertainty), intent to participate, decision readiness, and trial perceptions.
Results: 200 patients (86%) consented between May 2014 and April 2015. 100 were randomized
to each group. Surveys were completed by 87 in the DA group and 90 in the UC group. DA
group participants reported clearer values about trial participation than UC group participants
(LS-Mean=15.8 vs. 32, p<0.0001) and less uncertainty (LS-Mean=24.3 vs. 36.4, p=0.025). The
DA group had higher objective knowledge than the UC group (LS-Mean=69.8 vs. 55.8,
p<0.0001). There were no differences between groups in intent to participate.
Conclusions: Improvements on key decision outcomes including knowledge, self-efficacy,
certainty about choice, and values clarity among participants who viewed the DA suggest webbased DAs can support informed decisions about trial participation among cancer patients facing
this preference-sensitive choice. Although better informing patients prior to trial participation
could improve retention, more work is needed to examine DA impact on enrollment and
retention.
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Implications for Practice: This paper describes evidence about a decision tool to support
patients’ decisions about trial participation. By improving knowledge, helping patients clarify
preferences for participation, and facilitating conversations about trials, DAs could lead to
decisions about participation that better match patients’ preferences, promoting patient-centered
care and the ethical conduct of clinical research.
Gap between current and best practice: Although cancer clinical trials are an important
treatment option for many cancer patients and necessary for improving cancer care and
outcomes, there is a well-documented lack of informed decision making by patients facing
choices about clinical trials and poor understanding of trials even among participants.
Interventions are needed to better support patients’ decisions about trial participation.
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BACKGROUND
Cancer clinical trials are essential to evaluate new therapies and advance evidence based
treatments. However, despite the widespread availability of cancer clinical trials in academic and
non-academic settings, patients often are not well informed about trials and do not make
informed decisions about participation. Many patients harbor therapeutic misconceptions about
the aim of clinical trials[1, 2] and overestimate benefits of standard treatment[3]. In a recent
meta-analysis of 103 studies, over 25% of clinical trial participants did not understand the nature
of the study they were participating in or the voluntary nature of participation[4]. Only about
50% of participants understood central trial concepts such as the use of placebos or
randomization[4]. Furthermore, members of the general public frequently have misconceptions
about clinical trials, with nearly half of respondents believing that research participants do not
always receive the best possible care[5].
Without an adequate understanding of trials and trial procedures, patients cannot make a
fully informed decision about participation, a principal tenet of the ethical conduct of clinical
research. While a number of interventions have been developed to improve clinical trial
informed consent, nearly all focus exclusively on improving patients’ knowledge[6, 7]. Even
with the implementation of such interventions, a recent meta-analysis found that participant
understanding of important concepts essential for informed consent has not increased over the 3
decades of studies examined[4]. To improve cancer clinical trial decision quality, interventions
must go beyond knowledge provision to address aspects such as preference deliberation and
decision preparedness, guiding patients through the trial decision making process[6, 8].
Patient decision aids (DAs; Figure 1) can be used to support high-quality cancer clinical
trial decisions. In a variety of contexts, DAs have reduced patients’ uncertainty about health
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decisions, improved patients’ knowledge about decisions, improved patient-provider decision
communication, and improved the match between patients’ values and their health choices[9].
DAs incorporate values clarification exercises that help individuals address fears, concerns, and
preferences for options. These concerns and preferences might be particularly important for
racial and ethnic minority populations typically excluded from trials, in part because of concerns
and misinformation about clinical research[10, 11]. By improving knowledge about trials,
clarifying patients’ preferences for participation, and facilitating conversations about trials, DAs
could improve decisions about participation that better match patients’ preferences, promoting
patient-centered care and the ethical conduct of clinical research. They could also improve trial
retention rates, particularly among those who hesitate to participate based on misinformation
about trials, if patients become more informed and aware of trials and details prior to
participation. Given that there is often limited time for deliberation once a patient becomes trialeligible, implementing DAs about cancer clinical trials at multiple points in the cancer care
continuum, even before patients are eligible for a trial, can prepare patients to make a choice
about trial participation if or when one is offered to them.
The purpose of this study was to compare a web-based DA to our cancer center’s usual
care website in a randomized trial, examining whether and how the DA improves four elements
of decision making about cancer clinical trial participation: knowledge, self-efficacy,
preparedness to make a decision about trial participation, and intent to participate in a trial. Our
hypothesis was that implementing the DA would improve each of these outcomes, increasing
knowledge, self-efficacy, preparedness to make a decision about trial participation, and intent to
participate in a trial among recently diagnosed cancer patients. A secondary hypothesis was that
the DA would improve outcomes at a greater rate for racial minorities.
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METHODS
Decision Aid
The eight-section web-based DA was developed based on cancer survivor input in
accordance with best practices in health literacy. t concentrates on knowledge, empowerment,
and values clarification, aiming to correct common misconceptions about trials while promoting
preference deliberation (Figure 1). It is intended to prepare patients to have an informed
conversation about cancer clinical trial participation should one be offered to them.
In previous work, semi-structured interviews were conducted with 45 Hispanic and Black
cancer survivors representative of the prior population of interest. Feedback about attitudes,
barriers, and facilitators toward cancer clinical trial participation elicited in those interviews was
incorporated into the initial DA. The DA was then refined after usability testing with 10
additional minority survivors. It was found to improve knowledge, self-efficacy, and
preparedness to make a decision about cancer clinical trial participation in pilot testing with 64
Hispanic and Black cancer survivors. In a previous phase of the current study, a survey of 30
key stakeholders (e.g., principal investigators, institutional review board members) at an
institution outside its initial development revealed high acceptability of the DA among those who
develop and deliver informed consent (Kuzemchak MD, Byrne MM, Kaphingst KA, Politi, MC:
Stakeholder Perceptions of a Web-Based Decision Aid to Improve Cancer Clinical Trial
Informed Consent, under review). Feedback was incorporated prior to the current phase.
The final DA includes eight sections: Introduction, About Studies, Common Questions,
Talking to Your Doctor, What’s Important to You, Research Terms, and Additional Resources
(Figure 1). It includes an interactive education component explaining common trial concepts,
hypothetical patient stories illustrating choices a patient could make (to participate or to not
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participate, both in the context of existing effective standard treatment and in the context of no
existing effective standard treatment), and an interactive values clarification component in which
users slide a toolbar to indicate their perceived importance of various trial attributes. Generic in
nature, the DA is intended to supplement existing trial-specific informed consent documents.
In the current phase, we evaluated the effectiveness of the web-based DA in comparison
to an enhanced usual care control in a diverse population of newly diagnosed cancer patients.
The trial was registered with clinicaltrials.gov (protocol number: NCT01964222) prior to data
collection[12].
Participants
Participants were recruited in various cancer clinics within a major urban academic
medical center. Adults 18 or older who had been diagnosed with cancer in the past six months
and who had not previously participated in a cancer clinical trial were eligible to participate.
Consistent with the intent of the tool and the fact that trial eligibility can change across the care
continuum, patients were included whether or not they were a trial candidate at the time of study
enrollment. Eligible participants were identified through clinician referrals and/or through review
of medical records by a member of the research team.
Data Collection
Eligible patients were approached during clinic visits. At the direction of clinic staff,
trained research assistants invited eligible patients to participate in the waiting room and/or in the
exam room. Eligible patients had had no prior contact about the study. After a brief explanation
of the study, interested individuals completed a brief screening survey to confirm eligibility.
Written consent was obtained from those who were interested and eligible prior to viewing any
additional study materials. Participants were then allocated by a computer-generated random
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number sequence to one of two study conditions: DA or enhanced usual care (UC). Those
randomized to the DA group were instructed to view the web-based DA (Figure 1). Those
randomized to the UC group were instructed to view the institution’s website about cancer
clinical trials (Figure 2). Immediately after viewing one of the conditions, participants
completed a survey assessing cancer clinical trial knowledge, self-efficacy for finding cancer
clinical trial information, decisional conflict, intent to participate in a cancer clinical trial, and
cancer clinical trial perceptions. They also completed information about sociodemographic
characteristics and cancer type and stage. Participants could choose to complete the survey
online or on paper. They could complete it in the clinic at the time of consent on a tablet PC or at
home with a link to the website. For participants who opted to complete the intervention and
survey at the clinic, research assistants remained available to participants if they encountered
technical challenges, however, to reduce response bias, they did not stay with the participant as
he/she completed the survey.. Participants were allowed as much time as they needed to navigate
the website and to complete the survey. They were provided a $20 gift card for their time.
Measures
Knowledge
Eleven objective knowledge items evaluated how well participants understood cancer clinical
trials after viewing their assigned website (Appendix A). An overall knowledge score was
calculated for each participant with the percentage of items correctly answered, consistent with
the validated measure’s scoring procedures[13-15]. We examined whether there were
differences between the two groups in the average percentage of correct answers. Participants
were also asked to rank their self-perceived knowledge on a single-item 5-point Likert scale from
1=not at all knowledgeable to 5=completely knowledgeable.
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Self-Efficacy for Finding Information About Cancer Clinical Trials
Self-efficacy for finding information about cancer clinical trials was measured on a single-item
5-point scale with higher scores indicating greater self-efficacy for finding information.
Decisional Conflict
Evaluation of decisional conflict consisted of two subscales: the Values Clarity Subscale and the
Uncertainty Subscale of the low literacy version of the Decisional Conflict Scale[16]. Each
contains two items with three response categories. Following standard scoring guidelines for the
validated measure, each item was scored, then the sum was divided by 2 and multiplied by 25 to
produce overall “Values Clarity” and “Uncertainty” scores, respectively. Scores ranged from 1
to 100, with higher values representing less values clarity and less certainty, respectively.
Clarity of Opinions
Clarity of opinions about cancer clinical trials was measured on a single-item 5-point scale with
higher scores indicating clearer opinions.
Intent to Participate
Intent to participate in a cancer clinical trial was measured on a single-item 5-point scale with
higher scores indicating greater intent to participate.
Intent to Encourage Others to Participate
Intent to encourage others to participate in a cancer clinical trial was measured on a single-item
5-point scale with higher scores indicating greater intent to encourage others to participate.
Decision Readiness
Readiness to make a decision about whether to participate in a cancer clinical trial was measured
on a single-item 5-point scale with higher scores indicating greater readiness to make a decision.
Perceptions of Cancer Clinical Trials
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Participants’ perceptions of the pleasantness, safeness, easiness, helpfulness, value, convenience,
and goodness of cancer clinical trials were measured with individual items on a 7-point Likert
scale from 1=very unpleasant, very unsafe, etc. to 7=very pleasant, very safe, etc.
Implementation Outcomes
To evaluate the potential for implementation of the web-based DA, three implementation
outcomes were examined: time spent on the website, number of visits to the website, number of
participants who visited each page of the website in the DA group.
Sociodemographic Information
Sociodemographic information was collected including age, gender, cancer type, education,
income, ethnicity, race, language, and health literacy level[17].
Data Analysis
All analyses were conducted using Stata version 13. Descriptive statistics were calculated
for continuous and categorical variables. Bivariate analyses explored the relationship between
randomized group (DA or UC) and outcomes. Primary outcomes were knowledge and decisional
conflict; secondary outcomes were self-efficacy, intent to participate, decision readiness, and
trial perceptions. Because the outcome variables for secondary outcomes may not be interval
since they are measured using a Likert scale, we assessed the robustness of significant
differences in outcome by group assignment using non-parametric chi-square tests. As the nonparametric analyses showed the same results as the parametric analyses in terms of significant
differences by group assignment for these outcome variables, we only present results from the
parametric analyses. Controlling for whether or not participants had ever heard of cancer clinical
trials and educational attainment, multivariable linear regression models examined group (DA or
UC) on knowledge, self-efficacy for finding information about trials, decisional conflict (values
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clarity and uncertainty about choice), and intent to participate, decision readiness, and
perceptions of cancer clinical trials. Sample size was set at 180 (90 per group) to achieve 80%
power at α=0.05, using knowledge as the primary outcome and controlling for up to three
covariates. Statistical significance was set at 0.05 using two-sided analyses.
RESULTS
Participant Characteristics
Figure 3 details our recruitment and enrollment in a CONSORT diagram. A total of 200
patients were consented to participate out of 234 approached (86%) between May 2014 and April
2015. Patient-provided reasons for declining participation included being uninterested at that
time (20), having limited time (3), not feeling well (1), having difficulty reading (1), and none
(9). Of the consented patients, 100 were randomized to view the web-based DA (DA) while 100
were randomized to view the enhanced usual care website (UC). After viewing their assigned
website, surveys were completed by 87 participants in the DA group (87%), and 90 participants
in the UC group (90%). Reasons for incompletion included death (3 DA, 4 UC), failure to
complete in the study period (3 DA, 1 UC), voluntary withdrawal (6 DA, 5 UC), and ineligibility
due to screening failure (1 in DA). Individuals who did not complete the survey were
significantly older than those who did complete the survey (mean age 62.1 years (SD 2.2) vs.
55.0 (0.9) respectively: p=0.009), but did not significantly differ in any other measured
demographic characteristics. Table 1 displays demographic characteristics of the final sample.
There were no significant differences in demographic characteristics between individuals
randomized to the DA vs. the UC. Most participants (162/177, 91.5%) chose to view the website
at home rather than at their clinic visit, with 107 (60.5%) completing the survey by email, 44
(24.9%) by mail, and 11 (6.2%) by phone.

11

Bivariate Outcomes by Group
Participants in the DA group performed better on overall knowledge on the eleven-item
knowledge scale, answering an average of 73.7% of the items (8.1/11) correctly, compared to
61.5% (6.8/11) in the UC group (p=0.0001) (Table 2). The percentage of participants answering
correctly was greater in the DA group than in the UC group for all items, with statistically
significant differences between groups on four of the eleven items (Table 2). However, certain
items were frequently answered incorrectly by participants in both groups. In particular, items
about placebo use and study phases were answered correctly by fewer than half the participants
in both the DA and UC conditions (Table 2).
Table 3 shows mean scores on self-reported outcomes by group. Compared to those in
the UC group, those in the DA group had higher self-perceived knowledge about cancer clinical
trials (M=3.1 and 3.6, respectively, p=0.003), self-efficacy for finding information about cancer
clinical trials (M=3.5 and 4.1, respectively, p=0.0006), and clarity of opinions about cancer
clinical trials (M=3.5 and 3.9, respectively, p=0.0114). Those in the UC group also reported less
clear values and less certainty about choice compared to those in the DA group (M=31.5 and
16.7, respectively, p=0.0034 for values clarity; M=36.5 and 24.1, respectively, p=0.02 for
uncertainty). There were no significant differences in either the intent to participate in a cancer
clinical trial, or in the intent to encourage others to participate in a cancer clinical trial between
groups. There were no significant differences in participants’ perceptions of pleasantness,
safeness, easiness, helpfulness, value, convenience, or goodness of cancer clinical trials across
groups (data not shown in table).
Multivariable Analyses
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Table 4 summarizes outcomes of our multivariable models with intent to participate,
uncertainty, clarity of values, and knowledge of cancer clinical trials as the variables. Controlling
for whether or not participants had ever heard of cancer clinical trials and educational attainment,
there were no differences in intent to participate in cancer clinical trial. However, participants in
the DA group reported clearer values about trial participation than the UC group (Least SquaresMean=15.8 and 32. respectively, p<0.0001, and less uncertainty about participation (Least
Squares-Mean=24.3 and 36.4, respectively, p=0.025). Those in the DA group also had higher
objective knowledge scores than those in the UC group (Least Squares-Mean-69.8 and 55.8,
respectively, p<0.0001). There were no significant interactions of race/ethnicity and group
assignment in the multivariable analyses.
Because our outcome variables do not strictly meet the assumptions for OLS regressions,
we ran alternatively specified models using ordered logit regression (Intent, clarity of values and
uncertainty) and generalized linear models (knowledge) as a sensitivity analyses. There were no
changes in the significance of these outcome variables after controlling for whether or not
participants had heard of cancer clinical trials and educational attainment.
In exploratory analyses, we assessed whether race/ethnicity was associated with outcome
variables. In multivariable analyses controlling for whether or not participants ever heard of
cancer clinical trials and educational attainment, we found no significant difference when
comparing White non-Hispanics to all Others in intent to participate, clarity of opinions,
uncertainty, and knowledge.
Association of Objective Knowledge with Intent to Participate and Subjective Outcome
Variables
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We explored the association of the proportion of correct knowledge questions with
individuals’ intent to participate and subjective views on knowledge and decision readiness using
pairwise correlations. We found no significant association with knowledge and intent to
participate or intent to encourage others to participate. However, there were significant
associations between knowledge and variables for self-perceived knowledge, clarity of opinions,
uncertainty, and clarity of values, with higher levels of objective knowledge being associated
with higher perceived knowledge and decision readiness (Table 5). These significant associations
were maintained after controlling for group assignment, ever heard of cancer clinical trials, and
educational attainment in multivariate regressions (data not shown in tables).
Decision Aid Implementation Outcomes
Of the 86 participants in the DA group, data on implementation outcomes was available
for the 64 participants who opted to view the tool online rather than on paper. There were 94
unique visits to the website, with an average of 1.4 visits per participant. Participants spent an
average of 20.1 minutes on the website.
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DISCUSSION
Overall, participants who viewed the DA website performed better on key decision
outcomes than those who viewed the usual-care website. Although there was no difference in
participants’ intent to participate in a cancer clinical trial if one were offered, there were
statistically significant differences in decision-support factors such as their overall knowledge of
cancer clinical trials, self-perceived knowledge of cancer clinical trials, self-efficacy for finding
information about cancer clinical trials, certainty about choice, and values clarity. This suggests
that DAs can support informed decisions about trial participation among cancer patients faced
with this preference-sensitive choice.
Moreover, the DA was received positively by patients even among older adults who were
not comfortable using computers or the Internet. Our response rate (86%) and completion rate of
those enrolled (90% in the DA group) was high for a study on newly diagnosed cancer patients.
By offering multiple methods to complete the DA in both web- and paper-based formats, inside
and outside of the clinic environment, we were able to reach a range of participants. In our study,
61% of participants completed the study electronically outside of the clinic environment.
National studies of Internet use among older adults[18] suggest that approximately 58% of older
adults use the Internet in their home, and this number is growing. Electronic DAs such as this
one can be an important avenue for delivering cancer-related information, but steps should be
taken to ensure that patients regardless of computer literacy can benefit from the information
while there is still a sizable minority of the older adult population who might not be comfortable
using computers.
The DA discussed much of the information identified by key stakeholders as essential for
patients to understand about trial participation, to a diverse population of newly diagnosed cancer
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patients. Many of these points, such as the voluntary nature of trials and their potential risks and
benefits, correspond to current principles of informed consent and shared decision making.
Moreover, DAs that clearly explain what clinical trials aim to do could help alleviate therapeutic
misconceptions, an important barrier to informed consent[1, 2]. By improving patients’
knowledge of trial features and by helping them deliberate how they feel about those features,
DAs such as this one can facilitate informed, preference-sensitive choices among patients
considering a cancer clinical trial.
There are several reasons we might not have seen differences in intent to participate in
trials. Intent to participate is often related to cancer stage, and our patients had a mix of cancer
types and stages. It is possible that cancer type or stage contributed to this outcome, but given the
diversity of patients in the study, we did not have the power to explore specific disease
characteristics on outcomes. In addition, DAs are not designed to persuade individuals to
participate or not in a particular trial, thus intent might not be expected to change as a result of
this intervention. It is possible that retention rates could increase with the use of DAs as patients
match their decision about participation to their preferences, but this study was not designed to
measure changes in retention over time. Finally, intent was high in both groups. We did find
qualitative information that supported increased intentions to participate after viewing the DA.
For example, as one patient explained after viewing the DA website “this really has changed my
mind about clinical trials. When I was first diagnosed, my husband said no trials, we are doing
what they know works. Now I would have no objections [to participating].” Future studies of
specific cancer types or stages could explore the role of DAs on recruitment or retention rates.
In our study, we found that the DA website performed better than the usual care website
among both White and non-White patients. This finding suggests that DAs could help mitigate
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some of the racial disparities in trial knowledge, and self-efficacy for finding information about
trials. Future studies could look specifically at minority groups’ responses to the DA and/or
could develop targeted institutional based strategies to help address the disparities in trial
enrollment rates.
It is important to interpret these findings in the context of the study. The study was
conducted at a single academic medical center and results might not be generalizable to other
centers. The study included a mix of cancer types and stages, and it is possible that focusing on a
specific cancer type, stage, or type of clinical trial (phase I, II, or III) could lead to different
results. The study was cross-sectional and we did not track enrollment rates over time if patients
were offered trials. Future studies should explore these findings in diverse settings
longitudinally to confirm our results. Studies could also explore the role of DAs about specific
cancer clinical trials rather than trials in general.
CONCLUSIONS
Since the mid-1990s, government and academic organizations have worked together to
support cancer clinical trial participation, particularly among vulnerable subgroups of the
population such as racial and ethnic minorities[19, 20]. Our findings suggest that DAs such as
the one studied have the potential to improve informed consent and decision quality about cancer
clinical trials. They can help improve patients’ knowledge of cancer clinical trials and can help
them feel confident talking to clinicians about trials should one be offered to them. More
research is needed on ways to implement DAs about cancer clinical trials participation and how
to systematically measure their impact on trial decisions[21].
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Figure 1 Web-based Decision Aid
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Figure 2 Usual Care Website
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Figure 3 CONSORT Flow Diagram

20

Table 1 Participant Demographics (n=177)

Age
Gender

Diagnosis

Education
Annual
Household
Income
Ethnicity

Race

Ever heard of
trials
Single Item
Literacy

Mean
SD
Range
Male
Female
Bone
Breast
Gastrointestinal a
Gynecological b
Leukemia and
Lymphomas
Liver
Lung
Melanoma
Non-Melanoma Skin
Cancer
Prostate
Renal
Other c
≤ High School Degree
Some College
≥ College Degree
< $30,000
$30,000 - $60,000
$60,000 - $75,000
> $75,000
Hispanic
Non-Hispanic
African American
Asian
Caucasian
Native Am/Alaskan
Native
Other
Yes
No
Positive Screen
Negative Screen

Total
N=177
55.01
12.21
26-83
45 (25.42)
132 (74.58)
4 (2.26)
62 (35.03)
9 (5.08)
35 (19.77)
3 (1.69)

UC
N=90
54.03
12.07
26-80
22 (24.44)
68 (75.56)
3 (3.33)
35 (38.89)
2 (2.22)
18 (20.00)
1 (1.11)

DA
P-value
N=87
56.02
0.28
12.35
30-83
23 (26.44)
64 (73.56)
0.76
1 (1.15)
0.32
27 (31.03)
0.27
7 (8.05)
0.08
17 (19.54)
0.94
2 (2.30)
0.54

2 (1.13)
12 (6.78)
32 (10.08)
6 (3.39)

1 (1.11)
7 (7.78)
14 (15.56)
2 (2.22)

1 (1.15)
5 (5.75)
18 (20.69)
4 (4.60)

0.98
0.59
0.38
0.38

13 (7.34)
2 (1.13)
20 (11.30)
48 (27.12)
47 (26.55)
82 (46.33)
45 (28.85)
32 (20.51)
17 (10.90)
62 (39.74)
4 (2.26)
173 (97.74)
36 (20.34)
2 (1.13)
136 (76.84)
5 (2.82)

6 (6.67)
1 (1.11)
9 (10.00)
22 (24.44)
21 (23.33)
47 (52.22)
25 (31.25)
16 (20.00)
11 (13.75)
28 (35.00)
3 (3.33)
87 (96.67)
18 (20.00)
1 (1.11)
70 (77.78)
3 (3.33)

7 (8.05)
1 (1.15)
11 (12.64)
26 (29.89)
26 (29.89)
35 (40.23)
20 (26.32)
16 (21.05)
6 (7.89)
34 (44.74)
1 (1.15)
86 (98.85)
18 (20.69)
1 (1.15)
66 (75.86)
2 (2.30)

0.73
0.98
0.58

3 (1.69)
53 (29.94)
124 (70.06)
35 (20.96)
132 (79.04)

1 (1.11)
23 (2.56)
67 (74.44)
19 (22.09)
67 (77.91)

2 (2.30)
30 (34.48)
57 (65.52)
16 (19.75)
65 (80.25)

0.54

0.28

0.47
0.33
0.91
0.98
0.76
0.68

0.20
0.71
21

Screener (SILS)
Inadequate
11 (6.40)
5 (5.88)
6 (6.90)
REALM-SF
Marginal
33 (19.19)
13 (15.29)
20 (22.99)
Adequate
128 (74.42)
67 (78.82)
61 (70.11)
0.40
Results are presented as n (%) for all characteristics except age. UC = Usual Care. DA =
Decision Aid.
a
Includes colon cancer, pancreatic cancer, rectal cancer, stomach cancer, and throat cancer.
b
Includes cervical cancer, endometrial cancer, and ovarian cancer.
c
Includes rare cancers including bladder cancer, head and neck cancer, sarcoma, and rare forms
of GI cancer.

22

Table 2 Knowledge by Study Condition (n=177)

Percentage
Eleven Items
Participants
Correctly
Answered

Total
n=177

UC
n=90

DA
n=87

P-Value

67.5
(21.1)

61.5
(18.8)

73.7
(21.7)

<0.001

77.53

81.61

Ns

82.95

83.91

Ns

73.03

81.61

Ns

84.27

93.10

Ns

30.34

60.92

.0001*

39.33

58.62

.01*

20.22

48.28

.0001*

84.27

91.95

Ns

82.02

87.36

Ns

78.65

86.20

Ns

24.72

36.78

Ns

Only very sick patients are asked to take part in 79.55
a cancer research study.
Cancer research studies are the best way to
82.95
find out whether one treatment is better than
another.
Cancer research studies are only offered when
77.27
the doctor thinks there are no other treatment
options for a patient.
A patient can choose to stop being in a cancer
88.64
research study at any time, even after he or
she has signed the consent form and the study
Percentage has started.
Participants A patient can only be in a research study if his
45.45
Who
or her doctor recommends it.
Correctly
A cancer research study could not be offered to 48.86
Answered
a patient unless the new drug has been tested
Items
for safety in animals.
Cancer research studies almost never involve
34.09
the use of a placebo or sugar pill alone.
Cancer research studies follow strict guidelines
88.09
that are described in the study protocol.
A patient has to be in a research study if his or
84.66
her doctor recommends it.
Patients are asked to take part in cancer
82.39
research studies only when no other treatment
options are available.
A phase III cancer research study focuses on
30.68
finding the safety of new treatments.
Results are presented as mean (SD). UC = Usual Care. DA = Decision Aid.
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Table 3 Self-Reported Bivariate Outcomes by Study Condition (n=177)

Self-Perceived Knowledge About
Cancer Clinical Trials
Self-Efficacy for Finding Information
About Cancer Clinical Trials
Clarity of Opinions About Cancer
Clinical Trials
Intent to Participate in a Cancer
Clinical Trial
Intent to Encourage Others to
Participate in a Cancer Clinical Trial
Decision Readiness
Uncertainty
Unclear Values

Total
n=177
3.38
(1.1)
3.77
(1.1)
3.69
(1.1)
3.78
(1.1)
3.72
(1.1)
3.76
(1.1)
30.4
(35.4)
24.14
(33.8)

UC
n=90
3.09
(0.11)
3.5
(0.11)
3.49
(0.11)
3.78
(0.11)
3.72
(0.11)
3.63
(0.11)
36.52
(3.8)*
31.46
(3.9)*

DA
N=87
3.57
(0.12)
4.06
(0.11)
3.90
(0.12)
3.78
(0.11)
3.71
(0.12)
3.90
(0.12)
24.13
(3.6)
16.67
(3.1)

P-Value
0.003
<0.001
0.01
0.98
0.95
0.11
0.02
0.003

Results are presented as mean (SD). UC = Usual Care. DA = Decision Aid. The first six items
were rated on a 5-point Likert scale with higher scores representing higher self-perceived
knowledge, self-efficacy, etc. “Uncertainty” and “Unclear Values” were scored from 1 to 100
with higher values representing less certainty and less clear values, respectively.
*n=89
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Table 4 Multivariable Models Examining Group on Primary Outcomes, Controlling for Whether
or Not Patients Had Heard of Cancer Clinical Trials and Educational Attainment (n=177)
Intent
Group
Assignment
P-Value
Whether
Heard of
Cancer Clinical
Trials
P-Value
Education

Uncertainty

Unclear
Values

UC
DA

REF
-0.006 (0.16)
0.97

REF
-12.11 (5.38)
0.02

No

REF

REF

REF

REF

Yes

-0.28 (0.19)

0.05 (6.34)

9.18
(5.84)

-9.36 (3.41)

0.14

0.99

0.12

0.007

REF

REF

REF

REF

≤ High School
Degree
Some College
≥ College Degree

REF
-16.55 (4.96)
<0.001

Knowledge
REF
14.10 (2.89)
<0.001

-0.19 (0.22)
-0.62 (7.30)
-7.19 (6.74)
6.75 (3.93)
-0.340 (0.21)
1.78 (6.89)
-11.11 (6.35) 12.01 (3.70)
0.38
0.93
0.29
0.09
P-Value
0.05
0.80
0.08
0.001
Results are presented as coefficients and standard errors. UC = Usual Care. DA = Decision Aid.
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Table 5 Correlation of Intentions and Decision Outcomes with Objective Knowledge
Objective Knowledge (PropKCorrect)
ρ (p-value)
Intent to Participate in a Cancer
Clinical Trial
Intent to Encourage Others to
Participate in a Cancer Clinical Trial
Decision Readiness
Self-reported knowledge
Self-Efficacy for Finding Information
About Cancer Clinical Trials
Clear Opinions About Cancer
Clinical Trials
Uncertainty
Unclear Values

0.075 (p=0.32)
0.041 (p=0.59)
0.249 (p<0.001)
0.393 (p<0.001)
0.512 (p<0.001)
0.455 (p<0.001)
-0.314 (p<0.001)
-0.462 (p<0.001)
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Appendix A Objective Knowledge Items
1) Only very sick patients are asked to take part in a cancer research study.
2) Cancer research studies are the best way to find out whether one treatment is better than
another.
3) Cancer research studies are only offered when the doctor thinks there are no other
treatment options for a patient.
4) A patient can choose to stop being in a cancer research study at any time, even after he
or she has signed the consent form and the study has started.
5) A patient can only be in a research study if his or her doctor recommends it.
6) A cancer research study could not be offered to a patient unless the new drug has been
tested for safety in animals.
7) Cancer research studies almost never involve the use of a placebo or sugar pill alone.
8) Cancer research studies follow strict guidelines that are described in the study protocol.
9) A patient has to be in a research study if his or her doctor recommends it.
10) Patients are asked to take part in cancer research studies only when no other treatment
options are available.
11) A phase III cancer research study focuses on finding the safety of new treatments.
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